כניסה 
עקבו אחרינו בפייסבוק אונגלייזה - Onglyza
מתוך ויקירפואה
| אונגלייזה - Onglyza | ||
|---|---|---|
| מרכיב פעיל | SAXAGLIPTIN AS HYDROCHLORIDE | |
| שם התרופה | "אונגלייזה®" (קישור לדף התרופה במאגר משרד הבריאות) |
|
| סל הבריאות | לא כלול | |
התוויות |
Monotherapy: Onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Combination therapy: Add-on combination: Onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (TZD), or a sulfonylurea (SU), when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Initial combination: Onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate. Onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Onglyza has not been studied in combination with insulin
| |
| שם יצרן | BRISTOL MAYERS SQUIBB COMPANY , USA | |
| שם בעל הרישום | ASTRA ZENECA ISRAEL LTD | |